pre-IPO PHARMA

COMPANY OVERVIEW

Kashiv Biosciences, LLC is a premier, fully integrated biopharmaceutical company developing advanced-stage biosimilars and specialty biopharmaceutical products. The company is headquartered in Piscataway, NJ with facilities in Chicago, IL and India that all together provide formulation development, analytical testing, biosimilar characterization, and manufacturing of small and large molecules.


LOCATION


THERAPEUTIC AREAS


WEBSITE

None


CAREER WEBSITE

None


SOCIAL MEDIA


INVESTORS


PRESS RELEASES


Jul 5, 2023

Kashiv Biosciences Announces Successful Phase 1 Study Results of ADL018, A Biosimilar Candidate to Xolair (omalizumab)


May 31, 2022

Kashiv Biosciences Achieves Second U.S. Biosimilar Approval with FYLNETRA (pegfilgrastim-pbbk)


Mar 2, 2022

Kashiv Biosciences Receives Approval for Its First Biosimilar RELEUKOTM (filgrastim-ayow)


Nov 6, 2019

Amneal Enters into a Licensing Agreement with Kashiv BioSciences, LLC to Develop and Commercialize K127 for the Treatment of Myasthenia Gravis


Jan 3, 2019

Kashiv Pharma Acquires Adello Biologics and Becomes Kashiv BioSciences


For More Press Releases


Google Analytics Alternative